Triclabendazole
- Generic Name
- Triclabendazole
- Brand Names
- Egaten
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9Cl3N2OS
- CAS Number
- 68786-66-3
- Unique Ingredient Identifier
- 4784C8E03O
- Background
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. Fascioliasis is a parasitic infection often caused by the helminth, Fasciola hepatica, which is also known as “the common liver fluke” or “the sheep liver fluke” or by Fasciola gigantica, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food.
Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.
This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.
- Indication
This drug is indicated for the treatment of fascioliasis in patients aged 6 years old and above.
- Associated Conditions
- Fascioliasis
- Associated Therapies
- -
One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Universidad Peruana Cayetano Heredia
- Target Recruit Count
- 336
- Registration Number
- NCT06367361
Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)
- Conditions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT01931085
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.